Tirzepatide

Overview

A single molecule that activates two incretin receptors. In head-to-head and cross-trial comparison it produces the largest average weight loss of any approved pharmacotherapy, approaching the range of sleeve gastrectomy.

How it works

Agonises both the GIP and GLP-1 receptors. GLP-1 activity drives satiety and glucose-dependent insulin release; the added GIP component appears to improve insulin sensitivity, adipose handling of nutrients, and may blunt GLP-1-related nausea, allowing higher effective dosing.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

• Multiple phase 3 trials with active comparators, not just placebo.
• Sleep apnea approval was based on a dedicated randomized trial with objective polysomnography endpoints.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Best-in-class weight reduction Strong evidence

  SURMOUNT-1 reported roughly 21% mean body-weight reduction at 72 weeks on the 15 mg dose, with more than half of participants losing at least 20%.

• Superior HbA1c lowering Strong evidence

  Reductions up to about 2.4 percentage points, and superiority over semaglutide 1 mg in the head-to-head SURPASS-2 trial.

• Treats obstructive sleep apnea Strong evidence

  SURMOUNT-OSA showed large reductions in apnea-hypopnea index, leading to a specific FDA approval — the first drug approved for OSA.

• Favourable body-composition split Moderate evidence

  Sub-studies using imaging suggest a relatively high proportion of fat mass in total weight lost compared with diet alone, though lean loss still occurs.

• Blood pressure and lipid improvement Moderate evidence

  Consistent reductions in systolic blood pressure and triglycerides across the phase 3 program.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• Gastrointestinal side effects Moderate evidence

  Nausea, diarrhea, vomiting and constipation are dose-related and most common during escalation.

• Thyroid C-cell tumor boxed warning Serious

  Same rodent-derived contraindication as other incretin agonists: medullary thyroid carcinoma history or MEN2.

• Pancreatitis and gallbladder events Serious

  Uncommon but serious; rapid weight loss increases gallstone formation.

• Hypoglycemia in combination therapy Moderate evidence

  Risk rises substantially when added to sulfonylureas or insulin — those doses usually need reduction.

• Lean mass loss Moderate evidence

  As with all rapid weight-loss interventions, muscle is lost alongside fat without deliberate protein and resistance-training countermeasures.

• Anesthesia and aspiration risk Moderate evidence

  Delayed gastric emptying warrants pre-procedure planning.

• Counterfeit market Serious

  Regulators have seized counterfeit tirzepatide vials; grey-market "research" tirzepatide has no identity or sterility assurance.

Who should avoid it

• Medullary thyroid carcinoma or MEN2 history
• Pregnancy
• Severe gastroparesis
• Prior pancreatitis (relative)

If used under medical supervision, monitor

• HbA1c, glucose
• Weight and lean mass
• Hydration and renal function
• Concomitant insulin/sulfonylurea dosing

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

• Insulin and sulfonylureas — hypoglycemia risk rises substantially; doses typically need reducing
• Oral contraceptives — reduced effectiveness around dose escalation; a barrier method is advised for 4 weeks after each increase
• Oral medications generally — delayed gastric emptying affects absorption
• Anesthesia — pre-procedural withholding guidance applies

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Regulatory & legal status

Prescription drug. FDA has stated tirzepatide is no longer in shortage, which sharply restricts lawful compounding.

Infographic

Tirzepatide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Tirzepatide
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials
• DailyMed — official FDA prescribing information

Related peptides in Metabolic & Weight